Pfizer vs Sanofi India: share price, P/E, ROE and financials compared
Pfizer
Sanofi India
Pfizer and Sanofi India at a glance
Pfizer and Sanofi India are both listed in Healthcare. Pfizer is the larger by market cap, at ₹17,640 Cr against ₹7,561 Cr for Sanofi India (2.3 times as large). On valuation, Pfizer has the lower price-to-book (4.02× against 9.15×), while Sanofi India has the lower P/E (20.7× against 23.2×). On returns and margins, Pfizer has the higher operating margin (36.7% against 28.0%), while Sanofi India has the higher ROCE (58.5% against 22.9%) and the higher ROE (44.1% against 20.9%). Over three years, Pfizer has faster 3-year sales growth (+1.3% against −12.6% a year) and faster 3-year profit growth (+5.0% against −19.3% a year). Neither carries much debt for its equity: debt-to-equity is 0.04× for Pfizer and 0.02× for Sanofi India.
Key metrics, side by side
| Metric | PfizerPFIZER | Sanofi IndiaSANOFI |
|---|---|---|
| Price (₹) | 3,856.00 | 3,283.10 |
| Market cap (₹ Cr) | 17,640 | 7,561 |
| P/E | 23.2× | 20.7× (the lower figure, shaded) |
| P/B | 4.02× (the lower figure, shaded) | 9.15× |
| Dividend yield, trailing | 1.95% | 6.03% (the higher figure, shaded) |
| ROE | 20.9% | 44.1% (the higher figure, shaded) |
| ROCE | 22.9% | 58.5% (the higher figure, shaded) |
| Operating margin (OPM) | 36.7% (the higher figure, shaded) | 28.0% |
| Net margin (NPM) | 32.4% (the higher figure, shaded) | 20.0% |
| Sales CAGR 3Y | +1.3% (the higher figure, shaded) | −12.6% |
| Profit CAGR 3Y | +5.0% (the higher figure, shaded) | −19.3% |
| Debt to equity | 0.04× | 0.02× |
| Interest cover | 103.9× | – |
| Net profit TTM (₹ Cr) | 859 | 365 |
| 1Y return | −24.6% (the higher figure, shaded) | −28.9% |
| Promoter holding | 63.92% | – |
Pfizer vs Sanofi India: common questions
Which is bigger, Pfizer or Sanofi India?
By market cap, Pfizer is bigger at ₹17,640 Cr, against ₹7,561 Cr for Sanofi India (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹859 Cr for Pfizer and ₹365 Cr for Sanofi India.
Which has a lower P/E ratio, Pfizer or Sanofi India?
Pfizer trades at a P/E of 23.2× and Sanofi India at 20.7×. Sanofi India has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Pfizer or Sanofi India?
Pfizer reports a return on equity of 20.9% and Sanofi India 44.1%. Sanofi India has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Pfizer or Sanofi India?
Over the last three years: Sales grew +1.3% a year at Pfizer and −12.6% at Sanofi India, so Pfizer grew sales faster; profit grew +5.0% a year at Pfizer and −19.3% at Sanofi India, so Pfizer grew profit faster. Past growth doesn’t predict future growth.